The stakes could not have been higher. David Ard, former regional sales manager for Stryker Corp.’s biotechnology unit, faced charges of conspiracy and wire fraud related to the marketing of a bone growth product that hadn’t received U.S. Food and Drug Administration approval. He turned to Brent Gurney and Miranda Hooker of Wilmer Cutler Pickering Hale and Dorr.
Gurney, a partner, and Hooker, a counsel, assessed the case against their client as particularly weak, so they adopted a simple strategy: They refused to communicate with federal prosecutors. “The best defense often means staying silent,” Gurney said. “The U.S. attorney’s office never had any idea what we were going to argue. We kept it that way until the trial began.”
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
